No products in the cart.
Pre-made Nirsevimab benchmark antibody ( Whole mAb, anti-RSV therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-379
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Nirsevimab biosimilar, Whole Mab: Anti-RSV therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Nirsevimab is a passive immunisation, designed to provide RSV protection to all infants, whereby an antibody is given directly to an infant to help prevent RSV, unlike active immunisation, where a person’s immune system is activated to prevent or fight infection through a vaccine.
| Products Name (INN Index) | Pre-Made Nirsevimab biosimilar, Whole Mab: Anti-RSV therapeutic antibody |
|---|---|
| INN Name | Nirsevimab |
| Target | RSV |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | 5udc:HL:BC:EG |
| 99% SI Structure | None |
| 95-98% SI Structure | 4jha:HL/4jhw:HL |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | AIMM Therapeutics,MedImmune |
| Conditions Approved | NA |
| Conditions Active | Respiratory syncytial virus infections |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | RSV |
| Package |
Previous slide
Next slide
